Matthew Krantz, MD, from Vanderbilt University Medical Center

Sayantani Sindher, MD, is a clinical associate professor at the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine.

Jose Clemente, PhD, associate professor of Genetics and Genomics and Immunology at the Icahn School of Medicine at Mount Sinai

HCPLive Five: AAAAI 2026

2026 American Academy of Allergy, Asthma & Immunology (AAAAI)

 annual meeting in Philadelphia from February 27 – March 2, investigators presented new data spanning drug hypersensitivity, food 

 treatment, microbiome science, and biologic therapies for chronic inflammatory disease.

In this installment of HCPLive Five, the editorial team highlights 5 key expert interviews conducted on site, featuring insights from leading clinicians and investigators on emerging data. Topics include pharmacogenomic risk for lamotrigine-induced DRESS, adjunct biologic strategies for multi-allergen oral immunotherapy (OIT), microbiome modulation in infants born via cesarean delivery, and long-acting biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) and hereditary angioedema (HAE).

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

New research highlights a strong genetic association between the antiseizure medication lamotrigine and drug reaction with eosinophilia and systemic symptoms (Drug Reaction with Eosinophilia and Systemic Symptoms) among carriers of the HLA-A*32:01 allele. In an interview, Matthew Krantz, MD, of Vanderbilt University Medical Center, discussed prospective case-control findings conducted with Mass General Brigham showing 12-fold increased odds of lamotrigine-induced DRESS among HLA-A*32:01 carriers.

The multi-institutional analysis included 30 confirmed DRESS cases and 300 lamotrigine-tolerant controls from the BioVU biobank. Findings show the potential role of HLA genotyping in clarifying causality when multiple medications are involved and may inform future pharmacogenomic strategies to identify patients at elevated risk for severe lamotrigine hypersensitivity.

Dupilumab Reduces GI Symptoms During Multi-Allergen OIT, With Sayantani Sindher, MD

Findings from the COMBINE trial suggest the biologic dupilumab may improve tolerability and desensitization during omalizumab-facilitated multi-allergen OIT. In an interview, Sayantani Sindher, MD, from Stanford University, discussed results from the randomized study of 108 patients with multiple food allergies undergoing OIT. Although adding dupilumab did not significantly improve sustained unresponsiveness, it increased tolerance to higher allergen doses and reduced gastrointestinal adverse events.

Participants receiving dupilumab tolerated larger allergen exposures and experienced fewer GI symptoms per dose. Findings suggest dupilumab may serve as a targeted adjunct therapy to improve safety and patient experience during multi-allergen OIT.

Vaginal Seeding Partially Modifies Infant Microbiome in ACTIVATE, With Jose Clemente, PhD

Results from the ACTIVATE trial suggest vaginal microbial transfer may partially modify the infant gut microbiome in cesarean-delivered infants and influence early allergy risk. In an interview, Jose Clemente, PhD, from Icahn School of Medicine at Mount Sina, discussed findings showing that vaginal seeding increased colonization with beneficial microbes such as 

 shortly after birth and temporarily shifted microbiome profiles toward those seen in vaginally delivered infants. Although global microbiome differences diminished by 12 months, infants with successful microbial transfer showed lower levels of microbes associated with food sensitization.

Twice-Yearly Depemokimab Reduces Rescue Use in Recurrent CRSwNP, With Josesph Han, MD

A pooled post hoc analysis of ANCHOR-1 and ANCHOR-2 suggests the anti–IL-5 biologic depemokimab may improve disease control in patients with CRSwNP and prior surgery. In an interview, Joseph K. Han, MD, from Old Dominion University, discussed findings showing twice-yearly depemokimab improved nasal obstruction, sense of smell, and health-related quality of life compared with placebo in patients with type 2 inflammation. Depemokimab significantly reduced the need for rescue interventions such as systemic corticosteroids or additional surgery.

Navenibart at 3- and 6-Month Dosing Reduces HAE Attacks, With Adil Adatia, MD

Interim phase 2 ALPHA-SOLAR data suggest the investigational monoclonal antibody navenibart may provide durable prophylaxis for HAE types 1 and 2. In an interview, Adil Adatia, MD, from University of Alberta, reported that both 3-month and 6-month subcutaneous dosing schedules produced substantial reductions in HAE attacks, with median reductions exceeding 95%. The long-acting plasma kallikrein–targeting antibody demonstrated a favorable safety profile, with mostly mild treatment-emergent adverse events and few injection-site reactions.

Investigators also noted improvements in patient quality of life as attack frequency declined. Findings support continued evaluation of navenibart in the ongoing phase 3 ALPHA-ORBIT trial.

Videos

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

HCPLive Five at AAAAI 2026

ISHLT Provides Updates in Xenografting in Patients with Cardiac Diseases, With Anu Lala, MD

On February 20, 2026, the International Society for Heart and Lung Transplantation (ISHLT) released a consensus statement aiming to redefine the challenges and outline recommendations for moving forward in the field of xenotransplantation for end-stage 

This consensus statement builds on an existing document published in 2000, which highlighted the urgent need for donor organs for use in patients with cardiac and pulmonary diseases. To counter this, the authors indicated a potentially unlimited supply of hearts and lungs via pig organs. Of course, the document also acknowledged the natural barriers of antibody-mediated mechanisms in both the pig heart and the human recipient, which resulted in rejection after transplantation into non-human primates in earlier trials.

The 2026 consensus statement builds upon recent research, including the successful performance of 2 clinical heart xenotransplant cases. However, many of the challenges highlighted in the 2000 statement still linger 26 years later. As a result, the ISHLT committee behind the current statement designed it as a “living blueprint,” leaving it open for further editing and sculpting as the procedure is duplicated and thornier issues, such as ethical concerns, are worked out over time.

“This was a real tour de force,” Anuradha Lala, MD, professor of medicine, cardiology, and population health, director of the ACGME Fellowship in Advanced Heart Failure and Transplant, and Director of the Heart Failure Clinical Trials program at Mount Sinai Hospital, told 

 in an exclusive interview. “This document matters now because the field needed a living blueprint. We’ve had 2 human pig heart transplants, so we know that xenografts can function, but we also know that they can fail. We’re trying to learn why, and it’s an evolving process.”

The 2 successful xenografts lasted 60 and 40 days, respectively. The first, a 57-year-old man with advanced 

, underwent a challenging, yet ultimately successful, operation. Weeks 2 through 5 exhibited a stable trajectory, after which point the patient became unstable, showing hypotension, abdominal distension, and low output syndrome with low mixed venous saturation.

The second graft was more challenging; the patient, a 58-year-old man, suffered cardiac arrest prior to transplantation and developed renal dysfunction. By day 13, endomyocardial biopsy revealed antibody-mediated rejection (AMR), and by day 31, the patient required mechanical circulatory support following graft failure. Care was withdrawn on day 40.

These operations, although ultimately resulting in graft failure, proved greatly informative for clinicians, providing further data regarding immunosuppression and monitoring following xenotransplantation. The consensus statement also makes note of emerging techniques and tools, including gene expression profiling and donor-derived cell-free DNA in blood, to survey immunological challenges. However, they also acknowledge that these are largely underexplored in xenotransplantation. These, among other advancing mechanisms, are recommended for further study.

“People are dying on the wait list every day, and the reason, of course, is because we’re constrained by donor hearts in a way that no surgical innovation, including LVAD optimization, has been able to overcome,” Lala said. “Xenotransplantation, which at some previous point might have seemed like science fiction, is a real clinical necessity that we’re working towards in a very thoughtful, disciplined, and now structured way.”

Editors’ Note: Lala reports disclosures with Abiomed, AstraZeneca, Merck & Co., Novo Nordisk, Sequana, Bayer, and others.

1: Mehra MR, Mohiuddin MM, Reichart B, et al. The 2026 International Society for Heart and Lung Transplantation Consensus Statement on clinical cardiac xenotransplantation. J Heart Lung Transplant. Published online January 30, 2026. 

2: Cooper DKC, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: The Journal of Heart and Lung Transplantation. 2000;19(12):1125-1165. 

Lala discusses the ethical, medical, and practical concerns surrounding xenotransplantation of pig hearts – and how they should be addressed in clinical research.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

, the potential for 2 flare-free years could represent a fundamental shift in what GPP treatment can offer.

 interview with Neal Bhatia, MD, who reflected on the maintenance data emerging from the GEMINI trials for imsidolimab, Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor currently under 

US Food and Drug Administration (FDA) review

 with a PDUFA target date of December 12, 2026.

"You can imagine what that does to quality of life," Bhatia said of the roughly 2-year maintenance period without flares observed in the active treatment arm. Bhatia contrasted this with the limitations of older systemic options such as cyclosporine, characterizing them as slow-acting and burdened by tolerability concerns. These were considered drugs addressing GPP incompletely. The GEMINI data, in Bhatia’s view, represents a meaningful opportunity to extinguish flares that prior treatment paradigms could not reliably control.

On the question of where imsidolimab could fit within the treatment landscape if approved by FDA officials, Bhatia positioned it alongside spesolimab, the currently approved IL-36 inhibitor for GPP, as a natural companion in that targeted class. He acknowledged the real-world tendency among some clinicians to initiate treatment with IL-17 or IL-23 inhibitors given their accessibility and familiarity, but framed that only as a potential bridge. Getting patients to use an IL-36–modifying therapy, Bhatia expressed, should remain the clinical objective.

The therapy's reported favorable safety profile and low incidence of anti-drug antibody formation also carry practical weight in Bhatia's view, though he highlighted his own view suggesting none of it matters without an accurate diagnosis in hand. He recommended patients carry documentation of their confirmed GPP diagnosis to facilitate appropriate care in emergency or urgent care settings where treating clinicians may be unfamiliar with the condition. Equally important, he stressed, is ensuring these individuals have rapid access to infusion therapy at GPP flare onset.

Bhatia closed with a broader call to action for dermatologists, to advocate for GPP patients, embrace emerging targeted drugs, and resist ceding ground on rare inflammatory skin diseases to other specialties.

“This is a rare disease," Bhatia said. "This is not just a variant of psoriasis that I can try to knock down with other therapies that I have samples of."

The quotes contained in this interview summary were edited for clarity.

Bhatia reported serving as an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals.

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis. Vanda Pharmaceuticals, Inc. February 25, 2026. 

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html

Bhatia N. What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD. HCPLive. March 10, 2026. Accessed March 11, 2026. 

https://www.hcplive.com/view/what-the-significance-new-data-imsidolimab-gpp-neal-bhatia-md

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York

New findings from a cohort study, which identified 15,602 kidneys from 8544 donors in which > 1 kidney was transplanted out of sequence, meaning it bypassed standard allocation order, is occurring earlier, more broadly, and with less justification than its stated rationale supports.

Overall, investigators observed that out-of-sequence kidney transplants reached 4,595 in 2024, nearly 1 in 4 (22.6%) of all deceased donor kidney transplants, representing an approximate 10- to 17-fold growth across all out-of-sequence categories since 2020.

Study investigators defined out-of-sequence allocation by the presence of specific operational refusal codes appearing earlier in the match run than the eventual organ acceptance code. The primary comparison group consisted of unilateral out-of-sequence cases, donors from whom 1 kidney was placed through standard in-sequence allocation and the other was placed out of sequence, allowing for a paired analysis that controls for donor-level quality factors.

Unilateral out-of-sequence transplants, the fastest-growing category, increased 17-fold and accounted for 38.2% of all out-of-sequence transplants by the end of the study period.

The median sequence number at which OPOs first switched to out-of-sequence allocation dropped from 393 in 2020 to just 28 in 2024 for unilateral out-of-sequence cases. According to investigators, this means OPOs are bypassing the standard allocation list almost immediately, well before the point at which a kidney could be considered difficult to place. The number of transplant centers receiving offers before the out-of-sequence switch also decreased, from a median of 14 in 2020 to 10 in 2024.

In 50.5% of cases, 1 kidney from a donor was placed successfully through standard allocation, while the other kidney from the same donor was placed out of sequence. This unilateral pattern directly undermines the commonly cited rationale that out-of-sequence allocation is driven by organ quality concerns or donor-related factors, since both kidneys from a donor would be expected to have comparable underlying characteristics, explains investigators.

Median KDPI scores remained relatively constant across the study period and spanned the full 1% to 100% range, further suggesting organ quality is not the primary driver of these decisions.

Recipients of unilateral out-of-sequence kidneys were disproportionately older, male, White or Asian, privately insured, more highly educated, and more likely to have received a preemptive transplant, before starting dialysis, compared with recipients of the in-sequence kidney from the same donor.

For example, 17.1% of out-of-sequence recipients had a preemptive transplant versus 10.2% of in-sequence recipients (

< .001), and 29.1% had private insurance versus 23.0% (

 < .001). These patterns suggest that the out-of-sequence pathway is consistently benefiting more socioeconomically advantaged patients.

If OPOs were bypassing standard allocation primarily to ensure efficient placement, one would expect out-of-sequence kidneys to go to the same center that accepted the paired in-sequence kidney. Instead, the vast majority (85.7%) of out-of-sequence kidneys went to a different center, and traveled significantly farther (median 171 vs. 99 nautical miles), resulting in greater cold ischemia time, not less. Only 14.8% of unilateral out-of-sequence kidneys in 2024 went to the same center that received the partner kidney.

In adjusted Cox proportional hazards models, there were no statistically significant differences in patient survival (adjusted HR, 0.84; 95% CI, 0.70–1.02; P = .08) or death-censored graft survival (adjusted HR, 0.87; 95% CI, 0.70–1.08; P = .20) between unilateral out-of-sequence and unilateral in-sequence recipients. This held across both low- and high-KDPI groups. The additional flexibility created for transplant centers by the out-of-sequence pathway thus does not appear to translate into measurable improvements in transplant outcomes, as noted by study investigators.

spoke with study investigators Miko Yu, MD, from the Division of Nephrology in the Department of Medicine at Columbia University Irving Medical Center and the Columbia University Renal Epidemiology (CURE) Group in New York, and Joel Adler, MD, MPH, an Assistant Professor of Surgery, Division of Transplant Surgery, Department of Surgery and Perioperative Care at the Dell Medical School.

HCPLive: The central design of your study compares two kidneys from the same donor: one placed in sequence, one out of sequence. When you looked at how early in the match run OPOs were triggering out-of-sequence allocation for that second kidney, what did that tell you about whether organ quality is actually what's driving these decisions?

Yu: I think our findings call into doubt whether organ quality is truly driving these decisions. In the study we also looked at the refusal reasons for these types of kidneys and it does seem that the documented reasons are not overwhelmingly due to donor or organ related concerns such as donor history, biopsy findings or organ damage/mismatch, which you might expect if that second kidney went out of sequence very early on in the match run process.

HCPLive: If donor quality isn't the primary explanation, what is? You've seen the refusal code data, you've seen how uniformly this practice expanded across all 56 OPOs and across the full KDPI spectrum in just four years, what do you think is actually happening on the ground when an OPO decides to go out of sequence?

Yu: Speaking only from a data standpoint, it’s difficult to tease out and each OPO may have its own thresholds/procedures when deciding to go out of sequence. We have also shown in our other papers that there are certain common OPO and transplant center relationships (which are not necessarily geographically close to each other) that may also factor into their decisions when opting for the out of sequence pathway.

Adler: It is a complex problem that has long been managed through largely informal solutions. OPOs and transplant centers are operating under multiple external pressures, and when those pressures are not clearly aligned with shared goals, workarounds are almost inevitable.

HCPLive: Your data show that compared to recipients of the in-sequence mate kidney, out-of-sequence recipients were significantly more likely to be privately insured, more educated, and to have received a preemptive transplant. For patients who are lower on the waitlist, who may have been on dialysis for years and are waiting their turn, what is the real-world consequence of a kidney being pulled out of sequence before it ever reaches them?

Yu: The most immediate consequence would be that these patients who may have been waiting longer are skipped over for suitable offer for a kidney. Also, when a kidney goes out of sequence, transplant centers that were bypassed may not be aware at all that they received an offer for a kidney for their patients. So without a clear mechanism for expedited allocation, it’s not hard to see how the current practice can undermine overall trust in the organ allocation system.

HCPLive: Your adjusted survival analysis found no significant difference in patient or graft outcomes between the two groups. Does that finding vindicate the practice, complicate it, or neither , and what would you need to see in future data to feel confident drawing conclusions either way?

Yu: I think when we look at all the results together—that the in-sequence kidney in this set was by definition successfully placed via the standard allocation system, that there is no significant difference in outcomes between the groups, and that there are disparities in who receives a unilateral out of sequence transplant— it certainly brings up concerns about subjectivity in current out of sequence practices.

Adler: Trust is incredibly important. Even when transplant centers and OPOs are acting in good faith, opaque or inconsistently applied practices can still undermine public trust.

HCPLive: Right now there is no standardized threshold, no required justification, and no oversight mechanism governing when an OPO can go out of sequence. Given everything your study found, what is the single most important thing that would need to change, in policy, in data collection, or in accountability, before this practice can be considered equitable?

Yu: You’re right, I think all these factors – a standardized threshold, required justification and an oversight mechanism—should be incorporated or at least taken into account when we decide on future policies for an expedited allocation pathway. That said, I’m certain what happens the ground gets to be complicated so I’ll defer to Joel on this one.

From a data standpoint, I think refusal reasons could be captured better—there is a large proportion that are categorized as “Other” which further add to the lack of transparency.

Adler: At the end of the day, there is very little debate that some form of rescue or expedited allocation pathway is needed. The challenge is deciding how to implement it, how to monitor it, and how to remain flexible as conditions change. That will only become harder with a rapidly evolving donor pool, increased federal oversight, and greater media scrutiny—but it is exactly the work the field needs to do to move forward while maintaining public trust.

Editor’s Note: Adler reports relevant disclosures with RTI International. Yu reports no relevant disclosures. 

Yu ME, Husain SA, Tucker EG, et al. Expedited Transplant Allocation Using a Paired Kidney Cohort. 

https://doi.org/10.1001/jamanetworkopen.2026.0257

Adler JT, Sharma S. Out of sequence allocation: a necessary innovation or a new inequity in transplantation? 

. Published online September 1, 2024. doi:

https://doi.org/10.1016/j.ajt.2024.09.022

Articles

Out-of-sequence deceased-donor kidney placement expanded rapidly from 2020–2024, reaching 22.6% of transplants in 2024, with unilateral out-of-sequence cases driving growth. OPOs initiated bypass increasingly early in the match run, often after few center offers, and frequently when the mate kidney was successfully placed in-sequence—undermining organ-quality rationales. KDPI distributions were stable across the spectrum. Recipients skewed toward socioeconomically advantaged profiles, while organs traveled farther with longer cold ischemia. Adjusted patient and graft outcomes were similar, elevating equity and transparency concerns.

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Is Expedited Kidney Donation More Effective Than In-Sequence?

Vice Chief of Education, Fellowship Program Director

Division of Gastroenterology and Hepatology at UNC Health Care

Can Crohn’s Induction Move Beyond Infusions? AFFIRM Trial Insights

New data from the AFFIRM trial suggest that a fully subcutaneous induction strategy with risankizumab (Skyrizi) may deliver strong efficacy while offering a more convenient treatment pathway for patients with Crohn’s disease, adding to the growing body of evidence supporting IL-23 inhibition in this patient population.

First approved for Crohn’s disease in 2022, risankizumab has historically required intravenous induction before transitioning to subcutaneous maintenance dosing. In an interview discussing the AFFIRM results, lead investigator Millie Long, MD, MPH, chief of the division of gastroenterology and hepatology at the University of North Carolina, Chapel Hill noted that evaluating a subcutaneous induction approach represents an important step toward making effective therapy more accessible.

“Previously, risankizumab had been incredibly promising,” Long told 

. “This is obviously an approved agent, but it required IV induction, and so now allowing for a very effective therapy in a subcutaneous load allows us to reach more patients and to potentially get drug in the hands of patients quicker in terms of not having to wait for infusion center chairs, and hopefully will allow us to improve outcomes for those patients.”

The global, phase 3, randomized, placebo-controlled, double-blind AFFIRM study assessed the efficacy and safety of risankizumab SC as an induction treatment in adult patients with moderately to severely active Crohn's disease, with co-primary endpoints of percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12.

“In any induction clinical trial, we look at co primary endpoints, meaning we want to make sure that patients are feeling better in terms of clinical remission, but we also want to make sure that there is an endoscopic response, meaning that the actual inflammation visualized at the level of the endoscopy is improving,” Long explained.

In AFFIRM, a total of 289 patients were randomly assigned in a 2:1 ratio to risankizumab SC or placebo. Results showed significantly greater proportions of patients treated with risankizumab SC induction achieved CDAI clinical remission (55% vs 30%; P <.0001) and endoscopic response (44% vs 14%; P <.0001) at week 12 compared to placebo. Among patients with clinical response after 12 weeks of risankizumab SC induction treatment followed by 12 weeks of maintenance, 67% achieved CDAI clinical remission at week 24 and 57% achieved endoscopic response at week 24.

Long called attention to results in the advanced therapy-naïve population of the study, noting those treated with subcutaneous risankizumab achieved a 73.1% clinical remission rate and a 61.2% endoscopic response rate. She additionally cited encouraging results in patients with prior advanced therapy failure, further supporting risankizumab’s efficacy across patient populations. However, with the particularly strong results in biologic-naïve patients, Long suggests it may have potential as a first-line advanced therapy option in Crohn’s disease.

During the 12-week, double-blind, placebo-controlled period, the safety profile of risankizumab SC was consistent with the safety profile observed in Crohn's disease with no new safety risks observed.

Although the AFFIRM trial focused on a 12-week induction period, Long emphasized that durability and long-term safety data for risankizumab are supported by the broader clinical program evaluating the therapy and the IL-23 inhibitor class.

“The entire risankizumab portfolio and program now has many years of use and that's where the safety data really shine, that this is a highly effective, very safe drug where we're not seeing significant adverse effects in terms of infectious complications, we're not seeing malignancy risks, and really that long term data are what is so reassuring for the risankizumab portfolio,” Long said.

Editors’ Note: Long reports relevant disclosures with AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, Intercept, Janssen, Pfizer, Prometheus, Roivant, Sanofi, Takeda, and Target RWE.

Brooks A. AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease. HCPLive. March 2, 2026. Accessed March 11, 2026. 

https://www.hcplive.com/view/affirm-risankizumab-skyrizi-subcutaneous-induction-achieves-primary-endpoints-in-crohn-s-disease

Walter, K. FDA Approves Risankizumab For Crohn’s Disease. HCPLive. June 17, 2022. Accessed March 11, 2026. 

https://www.hcplive.com/view/fda-appropves-risankizumab-crohns-disease

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH

Wood discussed factors that go into shared decision making for multi-food allergy.

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

Daniel DiGiacomo, MD, a clinical immunologist at Hackensack Meridian Jersey Shore University Medical Center.

At AAAAI 2026, DiGiacomo discussed how artificial intelligence, genetic testing, and biomarkers could improve diagnosis and precision care.


AI, Genetic Testing May Advance Precision Care in Immunology, With Daniel DiGiacomo, MD

Caleb Alexander, MD, MS, is a professor of epidemiology and medicine at Johns Hopkins University School of Medicine and co-founder and principal of Stage Analytics.

Alexander discusses his recent study comparing 61 trials of 4 main GLP-1 RAs, highlighting their increased efficacy for weight loss in female patients.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 RA Effects are Largely Homogeneous but Stronger in Women than Men, With Caleb Alexander, MD, MS

In this episode, experts discuss solitary confinement, aging in prison, and gaps in care for incarcerated populations.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Throughout the year, hosts will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Medical Ethics Unpacked: Ethical Challenges of Carceral Healthcare

Explore emerging IBD treatments—TL1A blockers, microRNA, stem cells—and new small-bowel imaging, plus team-based care improving access.

UChicago Advances IBD Trials With Focus on Microbiome and Access

Senior Allergy Dietitian at the Royal Children’s Hospital, Clinician-Scientist Fellow at MCRI & Honorary Senior Research Fellow at Melbourne University,

McWilliam discussed findings from the TreEat study at AAAAI 2026.

Multi-Nut OFC Feasible, Comparable to Home Introduction in Infants With Peanut Allergy, With Vicki McWilliam, MND, PhD

Salvatore Viscomi, MD, is the chief executive officer of Carna Health.

Salvatore Viscomi, MD on closing CKD health disparities through community testing, AI equity, and accessible care for underserved populations.

Enhancing CKD Early Detection in High-Risk Populations Via Community Programs, AI, With Salvatore Viscomi, MD

María José Torres Jaén, MD, PhD, from Hospital Regional Universitario de Málaga.

At AAAAI 2026, Torres highlighted phase 3 peach immunotherapy research, nanostructure preclinical models, and a phase 2 prebiotic trial for LTP allergy.

Immunomodulation for Plant-Based Food Allergy, With María José Torres Jaén, MD, PhD

This interview highlights the significance of the potential FDA approval of imsidolimab for patients with generalized pustular psoriasis (GPP).

What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD

Bernard Kadosh, MD, is the medical director of the ventricular assist device and cardiogenic shock programs at NYU Langone Health.

Kadosh and Gorodeski discuss the value of including non-specialists in HF care and the challenges of prescribing 4 pills in a time of increasing medical distrust.

Latest News

HCPLive Five at AAAAI 2026

ISHLT Provides Updates in Xenografting in Patients with Cardiac Diseases, With Anu Lala, MD

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

Is Expedited Kidney Donation More Effective Than In-Sequence?

Risankizumab Subcutaneous Induction for Crohn’s Disease: Insights From the AFFIRM Trial, With Millie Long, MD, MPH